PRESS RELEASE published on 12/09/2025 at 14:50, 8 months 3 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 9 months 1 day ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
BRIEF published on 11/11/2025 at 08:05, 9 months 1 day ago Medincell élargit le rôle du Dr Grace Kim pour stimuler la croissance du capital américain Biotechnologie Medincell Stratégie Pharmaceutique Dr Grace Kim Croissance Du Capital Américain
PRESS RELEASE published on 11/11/2025 at 08:00, 9 months 1 day ago Informations privilégiées / Autres communiqués Medincell nomme le Dr Grace Kim au poste de Chief Strategy Officer, U.S. Finance, pour renforcer la croissance de son capital aux États-Unis. Découvrez son parcours et son rôle clé chez Medincell Croissance Chief Strategy Officer Medincell Dr Grace Kim Capital Américain
PRESS RELEASE published on 11/11/2025 at 08:00, 9 months 1 day ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 9 months 7 days ago Croissance continue pour Medincell et nouvelles perspectives avec l'Olanzapine LAI Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 11/05/2025 at 13:51, 9 months 7 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 9 months 7 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
PRESS RELEASE published on 11/05/2025 at 13:46, 9 months 7 days ago Informations privilégiées / Autres communiqués Medincell annonce la poursuite de la croissance d'UZEDY® et la préparation du dépôt de l'Olanzapine LAI sur le marché américain par Teva Pharmaceuticals Croissance Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 10/10/2025 at 22:16, 10 months 1 day ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
Published on 08/12/2026 at 15:42, 5 hours 22 minutes ago Critical Elements 10,000-Meter Summer Drill Program at Rose West Resumes with Positive Results
Published on 08/12/2026 at 15:42, 5 hours 22 minutes ago Critical Elements redémarre son programme de forage estival de 10 000 mètres à Rose Ouest avec des résultats positifs
Published on 08/12/2026 at 15:00, 6 hours 4 minutes ago Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America
Published on 08/12/2026 at 14:45, 6 hours 19 minutes ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/12/2026 at 19:57, 1 hour 6 minutes ago EQS-Adhoc: Hypoport SE: Hypoport SE resolves share buyback programme with a volume of up to EUR 10 million
Published on 08/12/2026 at 19:37, 1 hour 26 minutes ago EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
Published on 08/11/2026 at 17:45, 1 day 3 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 3 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 3 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 3 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
